Q-Line Biotech Ltd.
Q-Line Biotech Ltd. is an NSE SME IPO offering fresh equity shares worth approximately ₹214.48 crores, focused on manufacturing and distributing in-vitro diagnostic reagents, kits, and medical diagnostic equipment across India.
Overview
About the Company
Q-Line Biotech Ltd., incorporated in 2010 and operational since 2013, is a research-driven company based in Lucknow, Uttar Pradesh, engaged in developing, manufacturing, and marketing a broad range of reagents (including kits and point-of-care devices), consumables, and diagnostic equipment for the in-vitro diagnostics (IVD) sector. Its core product segments span Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and POC/Rapid Test devices. The company serves diagnostic service providers, hospitals, and medical colleges directly and through distributors. It has built its brands through R&D, reverse engineering, and technical collaborations with international partners. During the COVID-19 pandemic, it developed RT-PCR kits, RNA extraction kits, and VTM kits. As of March 31, 2026, the company had 362 permanent employees and 223 contract workers, with 19 dedicated R&D personnel.
Company Details
📋 Objects of Issue (Use of Proceeds)
- › Deployment of funds toward meeting the company's working capital requirements estimated at ₹93.50 crores.
- › Partial or full repayment/prepayment of certain existing borrowings of the company amounting to ₹90.00 crores.
- › Utilisation of remaining proceeds for general corporate purposes.
✅ Strengths
- ✓ Well-established manufacturing infrastructure with a strong emphasis on research & development, reverse engineering, and rigorous quality control processes.
- ✓ Diverse and comprehensive product portfolio covering multiple IVD segments including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and POC/Rapid Test devices.
- ✓ Pan-India distribution network with a presence across all four geographic regions of the country.
- ✓ Long-standing, stable relationships with a broad base of clients including hospitals, diagnostic service providers, and medical colleges.
- ✓ Experienced promoter group and seasoned management team with deep domain expertise in the diagnostics sector.
⚠️ Risks
- ! Bottom-line showed inconsistency over reported periods — FY25 net profit fell to ₹28.13 cr. despite significant revenue growth, partly due to an extraordinary item of ₹16.97 cr., raising questions about earnings sustainability.
- ! Contingent liability of ₹61.64 cr. as of December 31, 2025, represents a potential financial risk to the company.
- ! Total borrowings of ₹242.57 cr. as of December 31, 2025 indicate elevated debt levels, which could strain future cash flows.
- ! The company has no listed peers in India, making it difficult for investors to benchmark its valuation accurately and suggesting the IPO price may be stretched.
- ! The bumper profit of ₹38.69 cr. reported for 9M-FY26 raises concerns about its sustainability in subsequent periods, particularly post-IPO.
- ! The post-IPO NAV data is absent from the offer documents, limiting the ability to fully assess post-listing valuations.